title: A Multicenter, Open Label, Expanded Access Trial Of Maraviroc

summary: To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

design_allocation: Non-Randomized

lead_sponsor: ViiV Healthcare

location_country:
Malaysia
Greece
Romania
Australia
Belgium
Taiwan
India
Costa Rica
France
Argentina
Canada
Chile
Hong Kong
Netherlands
Switzerland
Ireland
Puerto Rico
Portugal
Germany
United States
United Kingdom
Italy
Austria
Mexico
Dominican Republic
Spain

location_facility: Hospital Universitario Virgen de La Macarena

location_facility: YR Gaitonde Centre for AIDS Research and Education (YRG CARE)

location_facility: Hospital Universitario Virgen de Las Nieves

location_facility: Desert Medical Group, Clinical Research Center

location_facility: Policlinico Tor Vergata, Divisione Malattie Infettive

location_facility: Landeskrankenhaus Graz West / Abteilung fuer Innere Medizin 1

location_facility: Universitair Ziekenhuis Gent, Inwendige Geneeskunde

location_facility: The Office of Dr. Zale P. Bernstein, MD.

location_facility: Hopital Tenon, Service des Maladies Infectieuses

location_facility: Fondazione Centro San Raffaele del Monte Tabor

location_facility: South Dayton Acute Care Consultants Inc.

location_facility: Denver Infectious Disease Consultants, PLLC

location_facility: The University of Texas Health Sciences Center at Houston

location_facility: University Hepatitis Center at Bach & Godofsky, MD,PA

location_facility: Clinica Malattie Infettive e Tropicali, Universita' degli Studi di Modena Reggio Emilia

location_facility: Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc.

location_facility: Garden State Infectious Disease Associates, PA

location_facility: Instituto Dominicano de Estudios Virologicos

location_facility: Universitaetsklinikum Carl Gustav Carus, Klinik und Poliklinik fuer Dermatologie

location_facility: Clinical Alliance for Research & Education - Infectious Diseases

location_facility: Hospital Regional Lic. Adolfo Lopez Mateos

location_facility: Universitair Ziekenhuis Gasthuisberg, Inwendige Geneeskunde

location_facility: Universitaetsklinikum Essen, HIV-Ambulanz, Hautklinik

location_facility: The Office of Dr. Gordon E. Crofoot, MD.

location_facility: Queen Elizabeth II Health Sciences Center

location_facility: Institutul de Boli Infectioase "Prof. Matei Bals"

location_facility: Sozialmedizinisches Zentrum Baumgartner Hoehe / 2. Interne Lungenabteilung

location_facility: Medizinische Hochschule Hannover, Klinische Immunologie, Zentrum Innere Medizin

location_facility: Internal Medicine Associates of Lee County

location_facility: Infectious Diseases Associates of Central Virginia

location_facility: Cliniques Universitaires Saint-Luc, Maladies Infectieuses

location_facility: Kaiser Permanente-Northwest Region, Immune Deficiency Clinic

location_facility: Canadian Immunodeficiency Research Collaborative

location_facility: Department of Infectious Disease, E-Da Hospital

location_facility: Dipartimento di Scienze Cliniche, Divisione Clinicizzata Malattie Infettive

location_facility: The Office of Dr. Daniel R. Coulston, MD

location_facility: Hopital de l'Hotel-Dieu, Service d'Hepato-Gastroenterologie

location_facility: Complejo Hospitalario Nuestra Señora de Valme

location_facility: The Office of Dr. Nicholaos C. Bellos, MD

location_facility: Istituto di Malattie Infettive e Tropicali

location_facility: Department of Medicine, St. John's Medical College Hospital

location_facility: Brighton and Sussex University Hospitals NHS Trust, The Elton John Centre

location_facility: Universita' degli Studi di Bari, Clinica Malattie Infettive, Policlinico

location_facility: Community Research Initiative of New England

location_facility: Instituto Nacional de Ciencias Medicas Y Nutricion Dr Salvador Zubiran

location_facility: Fundacion Huesped, Departamento de Investigacion Clinica

location_facility: Kansas University Internal Medicine Midtown Clinic

location_facility: Spitalul Clinic de Boli Infectioase Sf. Parascheva

location_facility: Department of HIV Medicine (I D Clinic), Jaslok Hospital & Research Centre

location_facility: Dipartimento di Malattie Infettive e Tropicali, Universita' di Roma La Sapienza

location_facility: University of Toledo - Health Science Campus

location_facility: Centre Hospitalier Cochin Saint Vincent de Paul

location_facility: Centre Hospitalier Universitaire Saint-Pierre, Maladies Infectieuses

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: Chu Pontchaillou, Service des maladies infectieuses

location_facility: Spitalul de Boli Infectioase si Tropicale Victor Babes

location_facility: IRCCS Lazzaro Spallanzani Istituto Nazionale per la Malattie Infettive

location_facility: Orange County Center for Special Immunology

location_facility: Hopital Pellegrin - Service des Maladies Infectieuses et Medecine Interne

location_facility: SOD Malattie Infettive, La Piastra dei Servizi

location_facility: Clinica Universitaria di Malattie Infettive, Ospedale Amedeo di Savoia

location_facility: Fund. de Gest. Sanitaria de L' Hospital de La Sta. Creu I Sant Pau

location_facility: Centro Hospitalar de Lisboa - Zona Central - Hospital Santo António Capuchos

location_facility: Reparto di Malattie Infettive, Azienda Sanitaria Locale

location_facility: Centre Hospitalier Universitaire de Charleroi, Médecine Interne

location_facility: Daniel Warner M.D., P.A. Consultive Medicine

location_facility: Azienda Ospedaliera San Giovanni Addolorata

location_facility: Hospital Clinico Universitario de Santiago de Compostela

location_facility: Unita Operativa di Malattie Infettive e Tropicali

location_facility: Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology

location_facility: Centre Hospitalier Universitaire de Caen

location_facility: IRCCS Lazzaro Spallanzani Istituto Nazionale per le Malattie Infettive

location_facility: IRCCS Lazzaro Spallanzani, Istituto Nazionale per le Malattie Infettive

location_facility: Gemeinschaftspraxis Dres. Rump und Usadel

location_facility: Unita' Operativa Clinica Malattie Infettive, Dipartimento di Medicina Interna e Malattie Infettive

location_facility: Instituut voor Tropische Geneeskunde, Inwendige Geneeskunde

location_facility: Infectious Disease Associates of Memphis

location_facility: Hamilton Health Sciences - McMaster University Medical Centre

location_facility: Hopital Bichat-Claude Bernard, Service des Maladies Infectieuses

location_facility: University of Oklahoma - Schusterman Clinic

location_facility: Uni. Politecnica delle Marche, Ist. Malattie Infettive e Medicina P.

location_facility: Universitaetsklinikum Koeln, Klinik I fuer Innere Medizin,

location_facility: Consorcio Hospital General Universitario de Valencia

location_facility: North Shore University Hospital, Department of Infectious Disease

location_facility: Hospital Clinic I Provincial de Barcelona

location_facility: Tarrant County Infectious Disease Associates

location_facility: General Hospital of Athens G. Gennimatas

location_facility: Hospital General Universitario de Alicante

location_facility: Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"

location_facility: Clinical Research Unit, Infectious Diseases

location_facility: Fundación para el Desarrollo de la Lucha contra el SIDA

location_facility: Arcispedale S. Anna Azienda Ospedaliera Universitaria di Ferrara

location_facility: Universita'Cattolica del Sacro Cuore Policlinico Gemelli

location_facility: Spitalul Clinic de Boli Infectioase Constanta

location_facility: Infectious Disease Specialists of Atlanta

location_facility: Hôpital Necker-Service des Maladies Infectieuses et Tropicales

location_facility: Department of Medicine Queen Elizabeth Hospital


title: A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease

summary: The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related quality of life (QoL), fistula healing, CD-related extra-intestinal manifestations, work performance, and overall activity.

status: Completed

study_completion_date_type: Actual

study_type: Interventional

primary_purpose: Treatment

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis. 2013 Feb;7(1):34-43. doi: 10.1016/j.crohns.2012.02.017. Epub 2012 Apr 4.

family: Louis

full_name: Edouard Louis

given: Edouard

sequence: first

family: Löfberg

full_name: Robert Löfberg

given: Robert

sequence: additional

family: Reinisch

full_name: Walter Reinisch

given: Walter

family: Camez

full_name: Anne Camez

given: Anne

family: Yang

full_name: Mei Yang

given: Mei

family: Pollack

full_name: Paul F. Pollack

given: Paul F.

family: Chen

full_name: Naijun Chen

given: Naijun

family: Chao

full_name: Jingdong Chao

given: Jingdong

family: Mulani

full_name: Parvez M. Mulani

given: Parvez M.

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Journal of Crohn's and Colitis

oa_host_type: publisher

evidence: open (via free pdf)

host_type: publisher

license_normalized: no license

version: publishedVersion

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

publisher_normalized: Oxford University Press

title: Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

lead_sponsor: Abbott

location_country:
Italy
Austria
Sweden
Switzerland
Spain
United Kingdom
Finland
France
Greece
Slovakia
Norway
Ireland
Belgium
Portugal
Denmark
Germany
Czech Republic

location_facility:
Site Ref # / Investigator 4626
Site Ref # / Investigator 3321
Site Ref # / Investigator 2978
Site Ref # / Investigator 3500
Site Ref # / Investigator 3075
Site Ref # / Investigator 3038
Site Ref # / Investigator 3618
Site Ref # / Investigator 3034
Site Ref # / Investigator 3487
Site Ref # / Investigator 3096
Site Ref # / Investigator 2982
Site Ref # / Investigator 3594
Site Ref # / Investigator 3071
Site Ref # / Investigator 3030
Site Ref # / Investigator 3081
Site Ref # / Investigator 2991
Site Ref # / Investigator 3051
Site Ref # / Investigator 3068
Site Ref # / Investigator 4590
Site Ref # / Investigator 2993
Site Ref # / Investigator 2999
Site Ref # / Investigator 3623
Site Ref # / Investigator 3027
Site Ref # / Investigator 2974
Site Ref # / Investigator 4603
Site Ref # / Investigator 3324
Site Ref # / Investigator 3064
Site Ref # / Investigator 3055
Site Ref # / Investigator 3023
Site Ref # / Investigator 3893
Site Ref # / Investigator 3017
Site Ref # / Investigator 3025
Site Ref # / Investigator 3008
Site Ref # / Investigator 3773
Site Ref # / Investigator 3019
Site Ref # / Investigator 3892
Site Ref # / Investigator 3013
Site Ref # / Investigator 4972
Site Ref # / Investigator 3098
Site Ref # / Investigator 3074
Site Ref # / Investigator 4595
Site Ref # / Investigator 4383
Site Ref # / Investigator 4607
Site Ref # / Investigator 3049
Site Ref # / Investigator 3015
Site Ref # / Investigator 4275
Site Ref # / Investigator 3448
Site Ref # / Investigator 4589
Site Ref # / Investigator 3076
Site Ref # / Investigator 3014
Site Ref # / Investigator 4355
Site Ref # / Investigator 3070
Site Ref # / Investigator 4588
Site Ref # / Investigator 4660
Site Ref # / Investigator 3493
Site Ref # / Investigator 3026
Site Ref # / Investigator 3035
Site Ref # / Investigator 4606
Site Ref # / Investigator 3620
Site Ref # / Investigator 3097
Site Ref # / Investigator 3084
Site Ref # / Investigator 3062
Site Ref # / Investigator 4596
Site Ref # / Investigator 3047
Site Ref # / Investigator 3895
Site Ref # / Investigator 3095
Site Ref # / Investigator 3061
Site Ref # / Investigator 4597
Site Ref # / Investigator 4584
Site Ref # / Investigator 4598
Site Ref # / Investigator 3596
Site Ref # / Investigator 3022
Site Ref # / Investigator 3000
Site Ref # / Investigator 3054
Site Ref # / Investigator 3020
Site Ref # / Investigator 3048
Site Ref # / Investigator 3072
Site Ref # / Investigator 3057
Site Ref # / Investigator 3042
Site Ref # / Investigator 4357
Site Ref # / Investigator 2988
Site Ref # / Investigator 4578
Site Ref # / Investigator 3080
Site Ref # / Investigator 3086
Site Ref # / Investigator 3079
Site Ref # / Investigator 2995
Site Ref # / Investigator 4604
Site Ref # / Investigator 2986
Site Ref # / Investigator 2977
Site Ref # / Investigator 3007
Site Ref # / Investigator 3896
Site Ref # / Investigator 3058
Site Ref # / Investigator 3036
Site Ref # / Investigator 3322
Site Ref # / Investigator 3033
Site Ref # / Investigator 3063
Site Ref # / Investigator 3056
Site Ref # / Investigator 3083
Site Ref # / Investigator 3041
Site Ref # / Investigator 3032
Site Ref # / Investigator 4657
Site Ref # / Investigator 2976
Site Ref # / Investigator 3040
Site Ref # / Investigator 3021
Site Ref # / Investigator 3090
Site Ref # / Investigator 3018
Site Ref # / Investigator 3011
Site Ref # / Investigator 3088
Site Ref # / Investigator 3031
Site Ref # / Investigator 3069
Site Ref # / Investigator 2975
Site Ref # / Investigator 2979
Site Ref # / Investigator 3039
Site Ref # / Investigator 2972
Site Ref # / Investigator 3488
Site Ref # / Investigator 4352
Site Ref # / Investigator 3091
Site Ref # / Investigator 3002
Site Ref # / Investigator 4358
Site Ref # / Investigator 3024
Site Ref # / Investigator 3326
Site Ref # / Investigator 3003
Site Ref # / Investigator 2985
Site Ref # / Investigator 2980
Site Ref # / Investigator 3368
Site Ref # / Investigator 3629
Site Ref # / Investigator 2969
Site Ref # / Investigator 3630
Site Ref # / Investigator 3486
Site Ref # / Investigator 3043
Site Ref # / Investigator 2997
Site Ref # / Investigator 4579
Site Ref # / Investigator 3093
Site Ref # / Investigator 3092
Site Ref # / Investigator 3794
Site Ref # / Investigator 3447
Site Ref # / Investigator 3073
Site Ref # / Investigator 3082
Site Ref # / Investigator 2970
Site Ref # / Investigator 2989
Site Ref # / Investigator 3323
Site Ref # / Investigator 3046
Site Ref # / Investigator 3010
Site Ref # / Investigator 3087
Site Ref # / Investigator 3094
Site Ref # / Investigator 4659
Site Ref # / Investigator 3953
Site Ref # / Investigator 3050
Site Ref # / Investigator 3489
Site Ref # / Investigator 4581
Site Ref # / Investigator 3065
Site Ref # / Investigator 3494
Site Ref # / Investigator 3052
Site Ref # / Investigator 2981
Site Ref # / Investigator 3085
Site Ref # / Investigator 4359
Site Ref # / Investigator 3484
Site Ref # / Investigator 3078
Site Ref # / Investigator 3619
Site Ref # / Investigator 3498
Site Ref # / Investigator 3012
Site Ref # / Investigator 4580
Site Ref # / Investigator 3044
Site Ref # / Investigator 4351
Site Ref # / Investigator 3029
Site Ref # / Investigator 3005
Site Ref # / Investigator 3325
Site Ref # / Investigator 4592
Site Ref # / Investigator 4586
Site Ref # / Investigator 3595
Site Ref # / Investigator 2996
Site Ref # / Investigator 2998
Site Ref # / Investigator 3066
Site Ref # / Investigator 4353
Site Ref # / Investigator 3625
Site Ref # / Investigator 2990
Site Ref # / Investigator 4591
Site Ref # / Investigator 3016
Site Ref # / Investigator 3089
Site Ref # / Investigator 3009
Site Ref # / Investigator 3499
Site Ref # / Investigator 2983
Site Ref # / Investigator 3045
Site Ref # / Investigator 3037
Site Ref # / Investigator 3077
Site Ref # / Investigator 3053
Site Ref # / Investigator 3617
Site Ref # / Investigator 2994
Site Ref # / Investigator 2973

intervention_type: Biological

lead_sponsor_type: industriel

status_simplified: Completed


ReferenceCitation: Ungar L, Rodriguez F, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Patel MR, Piccini JP, Mahaffey KW. Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. Cardiol Ther. 2019 Dec;8(2):283-295. doi: 10.1007/s40119-019-00146-6. Epub 2019 Aug 2.

family: Ungar

full_name: Leo Ungar

given: Leo

family: Rodriguez

full_name: Fatima Rodriguez

given: Fatima

family: Hellkamp

full_name: Anne S. Hellkamp

given: Anne S.

family: Becker

full_name: Richard C. Becker

given: Richard C.

family: Berkowitz

full_name: Scott D. Berkowitz

given: Scott D.

family: Breithardt

full_name: Guenter Breithardt

given: Guenter

family: Fox

full_name: Keith A. A. Fox

given: Keith A. A.

family: Hacke

full_name: Werner Hacke

given: Werner

family: Halperin

full_name: Jonathan L. Halperin

given: Jonathan L.

family: Hankey

full_name: Graeme J. Hankey

given: Graeme J.

family: Nessel

full_name: Christopher C. Nessel

given: Christopher C.

family: Singer

full_name: Daniel E. Singer

given: Daniel E.

family: Patel

full_name: Manesh R. Patel

given: Manesh R.

family: Piccini

full_name: Jonathan P. Piccini

given: Jonathan P.

family: Mahaffey

full_name: Kenneth W. Mahaffey

given: Kenneth W.

journal_name: Cardiology and Therapy

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

license: cc-by-nc

license_normalized: cc-by-nc

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: University of California - eScholarship University of California

repository_normalized: California Digital Library - eScholarship

evidence: oa repository (via pmcid lookup)

repositories: California Digital Library - eScholarship

repositories_institution: University of California - eScholarship University of California

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Quinn GR, Hellkamp AS, Hankey GJ, Becker RC, Berkowitz SD, Breithardt G, Fava M, Fox KAA, Halperin JL, Mahaffey KW, Nessel CC, Patel MR, Piccini JP, Singer DE. Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. J Am Heart Assoc. 2018 Aug 7;7(15):e008755. doi: 10.1161/JAHA.118.008755.

name: Smith Center for Outcomes Research Division of Cardiology Beth Israel Deaconess Medical Center Boston MA

name: Alaska Heart and Vascular Institute Anchorage AK

family: Quinn

full_name: Gene R. Quinn

given: Gene R.

name: Duke Clinical Research Institute Duke University School of Medicine Durham NC

name: Medical School The University of Western Australia Crawley Australia

name: University of Cincinnati College of Medicine Cincinnati OH

name: Department of Cardiovascular Medicine Hospital of the University of Münster Germany

name: Department of Psychiatry Massachusetts General Hospital Boston MA

name: University of Edinburgh and Royal Infirmary of Edinburgh United Kingdom

name: Mount Sinai School of Medicine New York NY

name: Department of Medicine Stanford University Stanford CA

name: Janssen Research & Development Raritan NJ

name: Division of General Internal Medicine Massachusetts General Hospital Boston MA

journal_name: Journal of the American Heart Association

publisher: Ovid Technologies (Wolters Kluwer Health)

ReferenceCitation: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019 Apr 1;5(2):145-152. doi: 10.1093/ehjqcco/qcy040.

name: Duke Clinical Research Institute, Department of Medicine, 2400 Pratt St, Durham, NC, USA

name: Division of Cardiovascular Health and Diseases, University of Cincinnati College of Medicine, 3590 Lucille Drive Suite 2700, Cincinnati, OH, USA

name: Thrombosis and Hemostasis Group, Bayer U.S. LLC, 11 Waterview Blvd., Parsippany, NJ, USA

name: Department of Cardiovascular Medicine, University of Münster, Albert-Schweitzer-Campus 1, Münster, Germany

name: Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Cres, Edinburgh, UK

name: Department of Neurology, Ruprecht-Karls-University, Im Neuenheimer Feld 672, Heidelberg, Germany

name: Cardiovascular Institute, Mount Sinai Medical Center, 1190 Fifth Avenue - 1 West, New York, NY, USA

name: The University of Western Australia, School of Medicine and Pharmacology, 35 Stirling Highway Perth WA, Australia

name: Department of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, USA

name: Janssen Research and Development LLC, 1000 US-202, Raritan, NJ, USA

name: Department of Medicine, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, USA

journal_name: European Heart Journal - Quality of Care and Clinical Outcomes

repository_institution: UWA - UWA Profiles and Research Repository

repositories_institution: UWA - UWA Profiles and Research Repository

ReferenceCitation: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. Am Heart J. 2018 Jun;200:102-109. doi: 10.1016/j.ahj.2018.02.013. Epub 2018 Feb 27.

title: Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF

ReferenceCitation: Leef GC, Hellkamp AS, Patel MR, Becker RC, Berkowitz SD, Breithardt G, Halperin JL, Hankey GJ, Hacke W, Nessel CC, Singer DE, Fox KAA, Mahaffey KW, Piccini JP. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. J Am Heart Assoc. 2017 Jun 14;6(6). pii: e004663. doi: 10.1161/JAHA.116.004663.

name: Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA

name: Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

name: University of Cincinnati College of Medicine, Cincinnati, OH

name: Bayer HealthCare Pharmaceuticals, Parsippany, NJ

name: Hospital of the University of Münster, Münster, Germany

name: Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY

name: School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia

name: Janssen Pharmaceutical Research and Development, Raritan, NJ

name: Massachusetts General Hospital, and Harvard Medical School, Boston, MA

name: University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

repository_institution: University of Edinburgh - Edinburgh Research Explorer

repository_institution: Harvard University - Digital Access to Scholarship at Harvard (DASH)

repositories_institution: Harvard University - Digital Access to Scholarship at Harvard (DASH)

repositories_institution: University of Edinburgh - Edinburgh Research Explorer

ReferenceCitation: Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Am J Cardiol. 2017 Jun 15;119(12):1989-1996. doi: 10.1016/j.amjcard.2017.03.028. Epub 2017 Mar 29.

ReferenceCitation: Sun Y, Hu D, Stevens S, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Fox KAA, Patel MR. Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thromb Res. 2017 Aug;156:184-190. doi: 10.1016/j.thromres.2017.04.010. Epub 2017 Apr 13.

ReferenceCitation: Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR; ROCKET AF Steering Committee and Investigators. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666.

name: From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.L., C.B.F., A.S.H., Y.L., J.P.P., M.R.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); Department of Cardiovascular Medicine, University of Münster, Germany (G.B.); Stanford University School of Medicine, CA (K.W.M.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Cardiovascular Institute,...

title: Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin

ReferenceCitation: Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation. 2016 Jul 5;134(1):37-47. doi: 10.1161/CIRCULATIONAHA.116.021890. Erratum in: Circulation. 2016 Aug 23;134(8):e114. Erratum in: Circulation. 2020 Feb 25;141(8):e98.

name: From Duke Clinical Research Institute, Durham, NC (C.B.F., A.S.H., Y.L., S.M.L., J.P.P., M.R.P.); University of Cincinnati College of Medicine, OH (R.C.B.); Bayer HealthCare Pharmaceuticals, Whippany, NJ (S.D.B); Department of Cardiovascular Medicine, Division of Electrophysiology, University Hospital Münster, Germany (G.B.); Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen...

title: On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin

ReferenceCitation: Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

name: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

name: The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY

name: Division of Electrophysiology, Department of Cardiovascular Medicine, Hospital of the University of Münster, Germany

name: Clinical Epidemiology Unit, General Medicine Division, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

name: Department of Neurology, Royal Perth Hospital, Perth, Australia

name: Global Clinical Development, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ

name: Janssen Research & Development, Raritan, NJ

name: Department of Medicine, Stanford University, Stanford, CA

name: University of Edinburgh, and Royal Infirmary of Edinburgh, UK

name: Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC

name: the ROCKET AF Steering Committee & Investigators

repository_normalized: University of Melbourne - Minerva Access

repository_institution: Aberdeen University - Aberdeen University Research Archive

repository_institution: Università degli Studi di Milano - Institutional Research Information System

repository_normalized: HELDA - Digital Repository of the University of Helsinki

repositories: HELDA - Digital Repository of the University of Helsinki

repositories: University of Melbourne - Minerva Access

repositories_institution: Aberdeen University - Aberdeen University Research Archive

repositories_institution: Università degli Studi di Milano - Institutional Research Information System

title: Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

ReferenceCitation: Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Califf RM, Fox KA, Patel MR; ROCKET AF Steering Committee & Investigators. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016 Jul 1;102(13):1036-43. doi: 10.1136/heartjnl-2015-308120. Epub 2016 Feb 17.

repository_institution: University of Oxford - Oxford Academic Notes & Queries

repositories_institution: University of Oxford - Oxford Academic Notes & Queries

title: Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

ReferenceCitation: Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016 Jan 26;133(4):352-60. doi: 10.1161/CIRCULATIONAHA.115.018544. Epub 2015 Dec 16.

name: From Duke Clinical Research Institute, Durham, NC (J.P.P., A.S.H., M.R.P.); Duke Heart Center, Duke University Medical Center, Durham, NC (J.P.P., J.B.W., M.R.P.); University of Cincinnati College of Medicine, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Whippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western...

ReferenceCitation: Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015 Oct;170(4):675-682.e8. doi: 10.1016/j.ahj.2015.07.006. Epub 2015 Jul 17.

title: Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

ReferenceCitation: Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR; ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.

ReferenceCitation: Singer DE, Hellkamp AS, Yuan Z, Lokhnygina Y, Patel MR, Piccini JP, Hankey GJ, Breithardt G, Halperin JL, Becker RC, Hacke W, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Investigators. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2015 Mar 3;4(3):e001349. doi: 10.1161/JAHA.114.001349.

name: Division of General Internal Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

name: School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia

name: Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany

name: Mount Sinai Medical Center, The Cardiovascular Institute, New York, NY

name: Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH

name: University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK

title: Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

ReferenceCitation: Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, Halperin JL, Califf RM, Fox KA, Becker RC. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014 Aug;54(8):917-27. doi: 10.1002/jcph.288. Epub 2014 Mar 26.

name: Janssen Pharmaceuticals Research & DevelopmentRaritanNJUSA

name: Duke Clinical Research InstituteDurhamNCUSA

name: Janssen Pharmaceuticals Research & DevelopmentTitusvilleNJUSA

name: Duke Translational Medicine InstituteDurhamNCUSA

name: University of Edinburgh and Royal Infirmary of EdinburghEdinburghUK

title: Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF

ReferenceCitation: Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014 May 6;129(18):1850-9. doi: 10.1161/CIRCULATIONAHA.113.005754. Epub 2014 Feb 19.

name: From the Division of Cardiovascular Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC (M.W.S., M.R.P., J.P.P., A.S.H., Y.L., R.M.C., R.C.B.); Department of Medicine, Division of Hematology and Thromboembolism, McMaster University, Hamilton, Ontario, Canada (J.D.D.); Department of Medicine, Division of Hematology, Hofstra North Shore/LIJ School of Medicine, Lenox Hill Hospital, New York, NY (A.C.S.); School of Medicine and Pharmacology, University of Western...

title: Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation

ReferenceCitation: Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM; ROCKET AF Investigators. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014 Mar 11;63(9):891-900. doi: 10.1016/j.jacc.2013.11.013. Epub 2013 Dec 4.

journal_name: Journal of the American College of Cardiology

title: Factors Associated With Major Bleeding Events

ReferenceCitation: Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013 Jun 18;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003.

title: Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy

ReferenceCitation: van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013 Jul;6(4):740-7. doi: 10.1161/CIRCHEARTFAILURE.113.000212. Epub 2013 May 30.

name: From the Divisions of Critical Care and Cardiology, University of Alberta, Edmonton, Alberta, Canada (S.v.D.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.S.H., M.R.P., R.C.B., K.W.M.); Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany (G.B.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Mount Sinai Medical Center, New York, NY (J.L.H.); Royal Perth Hospital, Perth, WA, Australia (G.J.H.); Johnson &...

title: Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation

ReferenceCitation: Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA; ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013 Feb 19;2(1):e000067. doi: 10.1161/JAHA.112.000067.

name: Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

name: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC

name: Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ

name: The Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY

name: Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany

name: Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia

name: Department of Neurology, Ruprecht‐Karls‐University, Heidelberg, Germany

title: Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial

ReferenceCitation: Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013 May 14;61(19):1998-2006. doi: 10.1016/j.jacc.2013.02.025. Epub 2013 Mar 14.

title: Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

ReferenceCitation: Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

name: From the Duke Clinical Research Institute (J.P.P., S.R.S., Y.L., M.R.P., K.W.M., R.C.B.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Massachusetts General Hospital and Harvard Medical School, Boston, MA (Y.C., D.E.S.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); Mount Sinai Medical Center, New York, NY (J.L.H.); Hospital of the University of Münster, Münster, Germany (G.B.); Royal Perth Hospital, Perth, Western Australia,...

title: Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation

ReferenceCitation: Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

ReferenceCitation: Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

repository_institution: Universidad Del Rosario - Repositorio Institucional E-DocUR

repositories_institution: Universidad Del Rosario - Repositorio Institucional E-DocUR

title: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

ReferenceCitation: ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.

title: Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

lead_sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

location_country:
Peru
Finland
Malaysia
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Czech Republic
Taiwan
Ukraine
India
France
Poland
Lithuania
Thailand
Norway
Argentina
Canada
Korea, Republic of
Colombia
South Africa
Chile
Sweden
Hong Kong
Netherlands
Philippines
Switzerland
Bulgaria
Singapore
Hungary
China
Germany
United States
United Kingdom
Austria
Brazil
Mexico
Venezuela
Israel
New Zealand
Spain
Turkey

title: A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation

summary: The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as non-central nervous system systemic embolism) in patients with non-valvular atrial fibrillation (a heart rhythm disorder).


title: A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis

summary: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

design_allocation: Randomized

ReferenceCitation: Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17. doi: 10.1093/ndt/gfq305. Epub 2010 Jun 3.

family: Carrera

full_name: F. Carrera

given: F.

family: Lok

full_name: C. E. Lok

given: C. E.

family: de Francisco

full_name: A. de Francisco

given: A.

family: Locatelli

full_name: F. Locatelli

family: Mann

full_name: J. F. E. Mann

given: J. F. E.

family: Canaud

full_name: B. Canaud

given: B.

family: Kerr

full_name: P. G. Kerr

given: P. G.

family: Macdougall

full_name: I. C. Macdougall

given: I. C.

family: Besarab

full_name: A. Besarab

family: Villa

full_name: G. Villa

given: G.

family: Kazes

full_name: I. Kazes

given: I.

family: Van Vlem

full_name: B. Van Vlem

family: Jolly

full_name: S. Jolly

given: S.

family: Beyer

full_name: U. Beyer

given: U.

family: Dougherty

full_name: F. C. Dougherty

given: F. C.

journal_name: Nephrology Dialysis Transplantation

oa_colors: green hybrid

evidence: open (via crossref license)

evidence: oa repository (semantic scholar lookup)

version: submittedVersion

location_country:
Italy
Austria
Switzerland
Netherlands
Spain
Germany
Finland
France
Australia
Belgium
Portugal
Denmark
Canada
United Kingdom


title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]

acronym: PLATO

summary: Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

ReferenceCitation: Thi Thu Nguyen T, Van Do D, Mellstrom C, Quang Nguyen T, Manh Pham H, Van Hoang S, Cong Luu T, Le Phuong T. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. Adv Ther. 2021 Jul;38(7):4026-4039. doi: 10.1007/s12325-021-01743-5. Epub 2021 Jun 11.

family: Thi Thu Nguyen

full_name: Thuy Thi Thu Nguyen

given: Thuy

family: Van Do

full_name: Dung Van Do

given: Dung

family: Mellstrom

full_name: Carl Mellstrom

given: Carl

family: Quang Nguyen

full_name: Tuan Quang Nguyen

given: Tuan

family: Manh Pham

full_name: Hung Manh Pham

given: Hung

family: Van Hoang

full_name: Sy Van Hoang

given: Sy

family: Cong Luu

full_name: Thinh Cong Luu

given: Thinh

family: Le Phuong

full_name: Tri Le Phuong

given: Tri

journal_name: Advances in Therapy

title: Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers’ Perspective

ReferenceCitation: Mahmoodi BK, Eriksson N, Vos GJA, Meijer K, Siegbahn A, James S, Wallentin L, Ten Berg JM. Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis. J Am Heart Assoc. 2021 Jun;10(11):e020025. doi: 10.1161/JAHA.120.020025. Epub 2021 May 17.

name: Department of Cardiology St. Antonius Hospital Nieuwegein the Netherlands

name: Division of Hemostasis and Thrombosis Department of Hematology UMC GroningenUniversity of Groningen the Netherlands

family: Mahmoodi

full_name: Bakhtawar K. Mahmoodi

given: Bakhtawar K.

name: Uppsala Clinical Research Center Uppsala University Uppsala Sweden

family: Eriksson

full_name: Niclas Eriksson

given: Niclas

family: Vos

full_name: Gerrit J. A. Vos

given: Gerrit J. A.

family: Meijer

full_name: Karina Meijer

given: Karina

name: Laboratory for Coagulation Research Clinical Chemistry Department of Medical Sciences University Hospital Uppsala Sweden

family: Siegbahn

full_name: Agneta Siegbahn

given: Agneta

name: Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden

family: James

full_name: Stefan James

given: Stefan

family: Wallentin

full_name: Lars Wallentin

given: Lars

name: The Cardiovascular Research Institute Maastricht (CARIM) Maastricht the Netherlands

family: ten Berg

full_name: Jurriën M. ten Berg

given: Jurriën M.

currency_apc_doaj: USD

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

repository_institution: Uppsala University - Uppsala University Publications

repositories_institution: Uppsala University - Uppsala University Publications

title: Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

ReferenceCitation: Gregersen I, Michelsen AE, Lunde NN, Åkerblom A, Lakic TG, Skjelland M, Ryeng Skagen K, Becker RC, Lindbäck J, Himmelmann A, Solberg R, Johansen HT, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Ueland T, Wallentin L, Halvorsen B. Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Heart Assoc. 2020 Sep;9(17):e016360. doi: 10.1161/JAHA.120.016360. Epub 2020 Aug 15.

name: Research Institute for Internal Medicine Oslo University Hospital Rikshospitalet Oslo Norway

name: Institute of Clinical Medicine Faculty of Medicine University of Oslo Norway

name: Section of Pharmacology and Pharmaceutical Biosciences Department of Pharmacy University of Oslo Norway

name: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center Uppsala University Uppsala Sweden

name: Department of Neurology Oslo University Hospital Rikshospitalet Oslo Norway

name: Division of Cardiovascular Health and Disease Heart, Lung and Vascular Institute Academic Health Center Cincinnati OH

name: AstraZeneca Research and Development Gothenburg Sweden

name: Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield United Kingdom

name: Department of Cardiology Stavanger University Hospital Stavanger Norway

name: Section of Clinical Immunology and Infectious Diseases Oslo University Hospital Rikshospitalet Oslo Norway

name: K.G. Jebsen TREC The Faculty of Health Sciences The Arctic University of Tromsø Tromsø Norway

repository_institution: University of Oslo - Duo Research Archive

repositories_institution: University of Oslo - Duo Research Archive

title: Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial

ReferenceCitation: Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA, Storey RF. Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thromb Haemost. 2020 Mar;120(3):412-422. doi: 10.1055/s-0039-1701011. Epub 2020 Jan 23.

name: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom

name: Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

name: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

name: Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden

name: AstraZeneca Research and Development, Gothenburg, Sweden

name: Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom

repository_institution: University of Leeds, The University of Sheffield, University of York - White Rose Research Online

repositories_institution: University of Leeds, The University of Sheffield, University of York - White Rose Research Online

title: Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study

ReferenceCitation: Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators. ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 2020 Jan;293:35-41. doi: 10.1016/j.atherosclerosis.2019.11.031. Epub 2019 Nov 29.

repository_institution: The Arctic University of Norway - Munin Open Research Archive

repositories_institution: The Arctic University of Norway - Munin Open Research Archive

title: ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

ReferenceCitation: Andersen T, Ueland T, Ghukasyan Lakic T, Åkerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker RC, Storey RF, Wallentin L, Siegbahn A, Kontny F. C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2402-2410. doi: 10.1161/ATVBAHA.119.312633. Epub 2019 Sep 26.

name: From the Department of Anaesthesiology, Stavanger University Hospital, Norway (T.A.)

name: Research Institute of Internal Medicine, the National Hospital (T.U., P.A., A.E.M.), University of Oslo, Norway

name: K.G. Jebsen Inflammatory Research Centre (T.U., P.A.), University of Oslo, Norway

name: Faculty of Medicine (T.U., P.A., A.E.M), University of Oslo, Norway

name: K.G. Jebsen – Thrombosis Research and Expertise Centre (TREC), University of Tromsø, Norway (T.U., P.A.)

name: Uppsala Clinical Research Centre (T.G.L., A.Å., M.B., S.K.J., L.W.), Uppsala University, Sweden

name: Department of Medical Sciences, Cardiology (A.Å., S.K.J., L.W.), Uppsala University, Sweden

name: Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Norway (P.A.)

name: Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, OH (R.C.B.)

name: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom (R.F.S.)

name: Department of Medical Sciences, Clinical Chemistry (A.S.), Uppsala University, Sweden

name: Department of Cardiology, Stavanger University Hospital, Norway (F.K.)

journal_name: Arteriosclerosis, Thrombosis, and Vascular Biology

title: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes

ReferenceCitation: Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD; PLATO Investigators. Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2019 Jul;213:57-65. doi: 10.1016/j.ahj.2019.04.006. Epub 2019 Apr 18.

title: Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Storey RF, Himmelmann A, Wallentin L, Angiolillo DJ; PLATO Investigators. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y(12) Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. J Am Heart Assoc. 2019 Mar 19;8(6):e011139. doi: 10.1161/JAHA.118.011139.

name: University of Florida, College of Medicine‐Jacksonville Jacksonville FL

name: Postgraduate Medical School Grochowski Hospital Warsaw Poland

name: Department of Cardiology Noordwest Ziekenhuisgroep Alkmaar Netherlands

name: Medizinishe Klinik Universitätsklinikum Heidelberg Heidelberg Germany

name: Hungarian Institute of Cardiology Semmelweis University Budapest Hungary

name: Lady Davis Carmel Medical Center Haifa Israel

name: Department of Infection, Immunity and Cardiovascular Disease University of Sheffield United Kingdom

name: AstraZeneca, Research and Development Gothenburg Sweden

repository_institution: University of Antwerp - Institutional Repository University of Antwerp

repository_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

repositories_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

repositories_institution: University of Antwerp - Institutional Repository University of Antwerp

title: Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

ReferenceCitation: Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.

name: Uppsala Clinical Research Center, Uppsala, Sweden

name: Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom

name: AstraZeneca Research and Development, Mölndal, Sweden

name: Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts

name: Baim Clinical Research Institute, Boston, Massachusetts

name: Stanford Center for Clinical Research, Stanford School of Medicine, Stanford, California

name: Assistance Publique-Hôpitaux de Paris; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France

name: Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France

name: NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom

title: Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes

ReferenceCitation: Inohara T, Pieper K, Wojdyla DM, Patel MR, Jones WS, Tricoci P, Mahaffey KW, James SK, Alexander JH, Lopes RD, Wallentin L, Ohman EM, Roe MT, Vemulapalli S. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. Am Heart J. 2018 Jul;201:25-32. doi: 10.1016/j.ahj.2018.03.013. Epub 2018 Mar 28.

title: Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome

ReferenceCitation: Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Wallentin L; PLATO (Platelet Inhibition and Patient Outcomes) Trial Investigators. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Heart Assoc. 2018 Jan 12;7(2). pii: e007009. doi: 10.1161/JAHA.117.007009.

name: Research Institute of Internal Medicine, The National Hospital, University of Oslo, Norway

name: K. G. Jebsen Inflammatory Research Center, University of Oslo, Norway

name: K. G. Jebsen–Thrombosis Research and Expertise Center, University of Tromsø, Norway

name: Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway

name: Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, OH

name: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom

name: Department of Cardiology, Stavanger University Hospital, Stavanger, Norway

name: the PLATO (Platelet Inhibition and Patient Outcomes) Trial Investigators

repository_institution: KTH Royal Institute of Technology - KTH Publication Database DiVA

repositories_institution: KTH Royal Institute of Technology - KTH Publication Database DiVA

title: Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

ReferenceCitation: Bellavia A, Wallentin L, Orsini N, James SK, Cannon CP, Himmelmann A, Sundström J, Renlund H, Lytsy P. Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart. 2017 Jun 1;4(2):e000557. doi: 10.1136/openhrt-2016-000557. eCollection 2017.

title: Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial

ReferenceCitation: Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017 Apr 14;6(4). pii: e005580. doi: 10.1161/JAHA.117.005580.

name: Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

name: Cardiovascular Division, Brigham and Women's Hospital, Boston, MA

name: Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany

name: Hospital Universitario La Paz, IdiPaz, Madrid, Spain

name: Département Hospitalo‐Universitaire FIRE, AP‐HP, Hôpital Bichat, Paris, France

name: Paris Diderot University, Sorbonne Paris Cité, Paris, France

name: FACT (French Alliance for Cardiovascular Trials), an F‐CRIN network, INSERM U1148, Paris, France

name: Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

repository_institution: Red Federada de Repositorios Institucionales de Publicaciones Científicas - LA Referencia

repositories_institution: Red Federada de Repositorios Institucionales de Publicaciones Científicas - LA Referencia

title: Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding

ReferenceCitation: Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L; PLATO Investigators. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8.

name: Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH

name: Cardiovascular Division, Brigham and Women's Hospital and Harvard Clinical Research Institute, Boston, MA

name: Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Germany

name: Department of Medicine, Stanford University, Stanford, CA

name: NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK

name: Department of Cardiovascular Science, University of Sheffield, Sheffield, UK

name: Henry Ford Heart and Vascular Institute, Detroit, MI

title: Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non–ST-Elevation Acute Coronary Syndrome

ReferenceCitation: Held P, Himmelmann A, Ditmarsch M. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10. Review.

name: Global Medicines Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden

title: Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program

ReferenceCitation: Johansson Å, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L; PLATO Investigators. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016 Apr 1;25(7):1447-56. doi: 10.1093/hmg/ddw012. Epub 2016 Jan 21.

title: Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

ReferenceCitation: Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr;102(8):617-25. doi: 10.1136/heartjnl-2015-308963. Epub 2016 Feb 4.

title: Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention

ReferenceCitation: Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BM. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016 Feb;9(2):e002951. doi: 10.1161/CIRCEP.115.002951.

name: For the author affiliations, please see the Appendix section.

journal_name: Circulation: Arrhythmia and Electrophysiology

title: Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

ReferenceCitation: Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D; PLATO Investigators. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015 Oct 9;4(10):e002490. doi: 10.1161/JAHA.115.002490.

name: Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden

name: Harvard Clinical Research Institute, Boston, MA

name: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

name: Medical Department, Hospital Unit West, Herning/Holstebro, Denmark

name: Hungarian Institute of Cardiology, Semmelweis University, Budapest, Hungary

name: Department of Cardiology, Vascular Medicine, Faculty of Medicine, Harapan Kita Hospital, National Cardiovascular Center, University of Indonesia, Jakarta, Indonesia

name: Département Hospitalo‐Universitaire FIRE, Assistance Publique‐Hôpitaux de Paris, Hôpital Bichat, Paris, France

name: Sorbonne‐Paris Cité, Université Paris‐Diderot, Paris, France

name: Department of Cardiovascular Science, University of Sheffield Sheffield, UK

repository_institution: Lund University - Lund University Publications

repositories_institution: Lund University - Lund University Publications

title: Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

ReferenceCitation: Hagström E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L; PLATO Investigators. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016 Apr 21;37(16):1325-33. doi: 10.1093/eurheartj/ehv491. Epub 2015 Sep 28.

title: Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study

ReferenceCitation: Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JH, Tricoci P, Lopes RD, Ohman EM, Roe MT, Harrington RA, Wallentin L. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18;4(6):e001512. doi: 10.1161/JAHA.114.001512.

name: Duke Clinical Research Institute, Durham, NC

name: Green Lane Cardiovascular Service, Auckland, New Zealand

name: Division of Cardiology, University of Alberta, Edmonton, Canada

name: Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

repository_institution: The Pennsylvania State University - CiteSeer X

repositories_institution: The Pennsylvania State University - CiteSeer X

title: Meta‐Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes

ReferenceCitation: Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, Becker RC; PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015 Jun;169(6):899-905.e1. doi: 10.1016/j.ahj.2015.03.015. Epub 2015 Mar 31.

title: Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

ReferenceCitation: Velders MA, Wallentin L, Becker RC, van Boven AJ, Himmelmann A, Husted S, Katus HA, Lindholm D, Morais J, Siegbahn A, Storey RF, Wernroth L, James SK; PLATO Investigators. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. Am Heart J. 2015 Jun;169(6):879-889.e7. doi: 10.1016/j.ahj.2015.02.019. Epub 2015 Mar 5.

title: Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

ReferenceCitation: Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12. doi: 10.1093/eurheartj/ehv116. Epub 2015 May 2.

title: Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

ReferenceCitation: Kholaif N, Zheng Y, Jagasia P, Himmelmann A, James SK, Steg PG, Storey RF, Westerhout CM, Armstrong PW. Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. Am J Med. 2015 Aug;128(8):914.e11-9. doi: 10.1016/j.amjmed.2015.03.005. Epub 2015 Mar 26.

title: Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex

ReferenceCitation: Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LÅ, Cannon CP, Harrington RA, Mark DB. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. doi: 10.1016/j.jacc.2014.11.034.

title: Economic Analysis of Ticagrelor Therapy From a U.S. Perspective

ReferenceCitation: Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan;101(2):119-25. doi: 10.1136/heartjnl-2014-305864. Epub 2014 Sep 16.

title: Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy

ReferenceCitation: Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK, Wallentin L, Held C. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov;100(22):1762-9. doi: 10.1136/heartjnl-2014-305619. Epub 2014 Jun 23.

title: Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes

ReferenceCitation: Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014 Jul;168(1):68-75.e2. doi: 10.1016/j.ahj.2014.04.001. Epub 2014 Apr 13.

title: Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15.

name: Duke Clinical Research Institute, Durham, NC, USA

name: Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, University of Cincinnati, Cincinnati, OH, USA

name: University of Colorado, School of Medicine Division of Cardiology and CPC Clinical Research, Aurora, CO, USA

name: AstraZeneca Research and Development, Wilmington, DE, USA

name: Medical Department, Hospital Unit West, Herning, Denmark

name: Department of Medicine, Division of Cardiology, Stanford University, CA, USA

name: Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

journal_name: European Journal of Preventive Cardiology

title: Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial

ReferenceCitation: Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATO study group. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014 Jun 14;35(23):1541-50. doi: 10.1093/eurheartj/ehu075. Epub 2014 Mar 28.

title: The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22;63(15):1493-9. doi: 10.1016/j.jacc.2014.01.038. Epub 2014 Feb 19.

title: Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

ReferenceCitation: Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420. Epub 2013 Oct 29.

name: From the Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (L.W., D.L., L.W., C.H., S.K.J.); Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center Uppsala University, Uppsala, Sweden (A.S.); Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH (R.C.B.); Department of Medicine, Stanford University, Stanford, CA (R.A.H., K.W.M.); TIMI...

title: Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization

ReferenceCitation: Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013 Sep;166(3):474-80. doi: 10.1016/j.ahj.2013.06.019. Epub 2013 Jul 26.

title: Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial

ReferenceCitation: Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK; PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30.

name: From INSERM-Unité 698, Paris, France (P.G.S.); Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France (P.G.S.); Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France (P.G.S.); Department of Medicine, Stanford University, Stanford, CA (R.A.H.); Astra Zeneca R&D, Mölndal, Sweden (H.E.); Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany (H.A.K.); Duke Clinical Research Institute, Duke University Medical Center,...

title: Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

ReferenceCitation: Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul;6(7):671-83. doi: 10.1016/j.jcin.2013.03.014.

title: Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)

ReferenceCitation: James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO Study Group. Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug;44(8):e95-6. doi: 10.1161/STROKEAHA.113.002069. Epub 2013 Jun 25.

title: Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials"

ReferenceCitation: James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO study group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May;44(5):1477-9. doi: 10.1161/STROKEAHA.111.000514. Epub 2013 Apr 9.

name: From the Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.K.J., L.W.); Duke Clinical Research Institute, Duke University, Medical Center, Durham, NC (K.S.P., R.C.B.); TIMI Study Group, Brigham and Women’s Hospital, Boston, MA (C.P.C.); Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom (R.F.S.); INSERM-Unité 698, Paris, France, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris,...

title: Ticagrelor in Patients With Acute Coronary Syndromes and Stroke

ReferenceCitation: Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013 Feb 12;127(6):673-80. doi: 10.1161/CIRCULATIONAHA.112.124248. Epub 2012 Dec 31.

name: From the TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (P.K, C.P.C.); the Division of Cardiology, University of California San Francisco, San Francisco CA (P.K.); the Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Sweden (L.W.); Duke Clinical Research Institute, Durham, NC (E.R.); AstraZeneca R&D, Wilmington, DE (J.H.); the Department of Cardiology, Århus University Hospital, Århus, Denmark...

title: Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

ReferenceCitation: Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, Husted S, Katus H, Claeys MJ, Storey RF, Asenblad N, James SK. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. Am Heart J. 2012 Nov;164(5):728-34. doi: 10.1016/j.ahj.2012.08.017. Epub 2012 Oct 17.

title: Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients—Results from the PLATelet inhibition and patient Outcomes (PLATO) study

ReferenceCitation: Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23;60(17):1623-30. doi: 10.1016/j.jacc.2012.07.021. Epub 2012 Sep 26.

title: Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

ReferenceCitation: Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8.

ReferenceCitation: Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012 Sep;164(3):334-342.e1. doi: 10.1016/j.ahj.2012.06.005. Epub 2012 Jul 26.

title: Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013 Jan;34(3):220-8. doi: 10.1093/eurheartj/ehs149. Epub 2012 Jun 19.

name: Center for Medical Technology Assessment, Linköping University, 581 83 Linköping, Sweden

name: Cardiology, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Department of Cardiology UHL, County Council of Östergötland, Linköping, Sweden

name: Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden

name: for the PLATO Health Economic Substudy Group

title: Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study

ReferenceCitation: James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012 Jun 12;125(23):2914-21. doi: 10.1161/CIRCULATIONAHA.111.082727. Epub 2012 May 9.

name: From the Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.K.J.); Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom (R.F.S.); AstraZeneca Research & Development, Wilmington, DE (N.S.K., J. Maya); Department of Cardiology, Århus University Hospital, Århus, Denmark (S.H.); Semmelweis University, Hungarian Institute of Cardiology, Budapest, Hungary (M.K.); Duke Clinical Research Institute, Durham, NC (K...

title: Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack

ReferenceCitation: Siha H, Das D, Fu Y, Zheng Y, Westerhout CM, Storey RF, James S, Wallentin L, Armstrong PW. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ. 2012 Jul 10;184(10):1135-42. doi: 10.1503/cmaj.111683. Epub 2012 Apr 30.

title: Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial

ReferenceCitation: Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L; Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18.

name: From the Canadian Heart Research Center and Terrence Donnelly Heart Center, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (S.G.G.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.C., K.S.P., K.W.M., R.A.H.); Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil (J.C.N.); Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom (R.F.S.); Southlake Regional...

title: Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor

ReferenceCitation: Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P, Harrington RA, Wallentin L. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012 Jan 24;125(3):514-21. doi: 10.1161/CIRCULATIONAHA.111.047530. Epub 2011 Dec 16.

name: From the University of Alberta, Edmonton, Canada (P.W.A., H.S., Y.F., C.M.W.); INSERM U-698, Assistance Publique-Hôpitaux de Paris, and Universite Paris-Diderot, Paris, France (G.S.); Uppsala University Hospital, Uppsala, Sweden (S.K.H.); University of Sheffield, Sheffield, United Kingdom (R.F.S.); AstraZeneca, Wilmington, MA (J.H.); University of Heidelberg, Heidelberg, Germany (H.K.); Copenhagen University Hospital, Copenhagen, Denmark (P.C.); Duke Clinical Research Institute, Durham, NC (R.A.H.);...

title: ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

ReferenceCitation: Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Erratum in: Eur Heart J. 2012 Nov;33(21):2750.

title: Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 2;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498. Epub 2011 Jun 27.

name: From the Duke Clinical Research Institute, Durham, NC (K.W.M., D.M.W., R.C.B., K.S.P., R.A.H.); AstraZeneca Research and Development, Wilmington, DE (K.C., J.H.); University of Sheffield, Sheffield, UK (R.F.S.); University of Florida College of Medicine–Jacksonville (D.J.A.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (C.H., S.J., L.W.); and TIMI Study Group, Brigham and Women's Hospital, Boston, MA (C.P.C.).

title: Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

ReferenceCitation: James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17;342:d3527. doi: 10.1136/bmj.d3527.

title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

ReferenceCitation: Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L; PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10;57(19):1908-16. doi: 10.1016/j.jacc.2010.11.056.

title: The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

ReferenceCitation: Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23;122(21):2131-41. doi: 10.1161/CIRCULATIONAHA.109.927582. Epub 2010 Nov 8.

name: From INSERM U-698, Paris, France (P.G.S.); Hôpital Bichat-Claude Bernard, AP-HP, Paris, France (P.G.S.); Université Paris 7, Paris, France (P.G.S.); Uppsala Clinical Research Center and Department Medical Sciences, Uppsala University, Uppsala, Sweden (S.J., S.O., L.W.); Duke Clinical Research Institute, Durham, NC (R.A.H., R.C.B.); Azienda Ospedaliero Universitaria di Parma, Parma, Italy (D.A.); TIMI Study Group, Brigham and Women's Hospital, Boston, Mass (C.P.C.); AstraZeneca Research and...

title: Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention

ReferenceCitation: James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30.

name: From the Uppsala Clinical Research Center, Uppsala, Sweden (S.J., L.W.); Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland (A.B.); Flinders Medical Centre, Bedford Park, Australia (P.A.); AstraZeneca Research and Development, Wilmington, Del (K.K.B., J.H.); TIMI Study Group, Brigham and Women’s Hospital, Boston, Mass (C.P.C.); Medisch Centrum Alkmaar, Alkmaar, the Netherlands (J.H.C.); Duke Clinical Research Institute, Durham, NC (R.A.H., D.W.); Universitätsklinikum Heidelberg,...

title: Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function

ReferenceCitation: Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13.

title: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

ReferenceCitation: Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.

repository_institution: University of Debrecen - University of Debrecen Electronic Archive

repositories_institution: University of Debrecen - University of Debrecen Electronic Archive

title: Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

ReferenceCitation: Molecule of the month. Ticagrelor. Drug News Perspect. 2007 May;20(4):264.

location_country:
Finland
Malaysia
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Czech Republic
Taiwan
Ukraine
India
France
Poland
Thailand
Slovakia
Norway
Argentina
Indonesia
Canada
Korea, Republic of
South Africa
Sweden
Hong Kong
Netherlands
Philippines
Switzerland
Bulgaria
Singapore
Hungary
Puerto Rico
China
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Israel
Georgia
Spain
Turkey